/COYA
COYA Stock - Coya Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$5.49+3.58%
+$0.19 (+3.58%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.21
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+209.7%upside
Target: $17.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for COYA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.44 – $5.54
TARGET (TP)$17.00
STOP LOSS$5.05
RISK/REWARD1:26.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.20
52W High$8.29
52W Low$4.65
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.55M | $6.00M | N/A | N/A | N/A |
| Gross Profit | $-8,311,593 | $500,679 | $-4,412,498 | N/A | N/A |
| Gross Margin | -233.9% | 8.3% | N/A | N/A | N/A |
| Operating Income | $-17,249,711 | $-7,903,349 | $-9,811,939 | $-4,870,310 | $-1,042,154 |
| Net Income | $-14,880,787 | $-7,987,836 | $-12,244,776 | $-4,891,792 | $-1,099,793 |
| Net Margin | -418.7% | -133.1% | N/A | N/A | N/A |
| EPS | $-0.98 | $-0.79 | $-1.23 | $-0.74 | $-0.42 |
Company Overview
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$16
Average Target
↑ 182.3% Upside
Now
$15
Low
$16
Average
$16
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 9th 2025 | Lake Street | Initiation | Buy | $16 |
| December 4th 2024 | D. Boral Capital | Initiation | Buy | $15 |
Earnings History & Surprises
COYABeat Rate
45%
Last 11 quarters
Avg Surprise
-58.6%
EPS vs Estimate
Beats / Misses
5/5
1 met exactly
Latest EPS
$-0.10
Q4 2025
EPS Surprise History
Q1 24
-42.3%
$0.15vs$0.26
Q2 24
-16.7%
$-0.35vs$-0.30
Q3 24
-35.7%
$-0.19vs$-0.14
Q4 24
+36.6%
$-0.26vs$-0.41
Q1 25
+30.8%
$-0.18vs$-0.26
Q2 25
0.0%
$-0.44vs$-0.44
Q3 25
-63.6%
$-0.36vs$-0.22
Q4 25
-600.0%
$-0.10vs$0.02
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 17, 2026 | $-0.08 | — | — | — |
Q4 2025 | Nov 12, 2025 | $0.02 | $-0.10 | -600.0% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.22 | $-0.36 | -63.6% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.44 | $-0.44 | 0.0% | = MET |
Q1 2025 | Mar 18, 2025 | $-0.26 | $-0.18 | +30.8% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.41 | $-0.26 | +36.6% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.14 | $-0.19 | -35.7% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.30 | $-0.35 | -16.7% | ✗ MISS |
Q1 2024 | Mar 19, 2024 | $0.26 | $0.15 | -42.3% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.37 | $-0.34 | +8.1% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.32 | $-0.31 | +3.1% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-0.43 | $-0.28 | +34.9% | ✓ BEAT |
Q1 2023 | Mar 29, 2023 | — | $-0.42 | — | — |
Q4 2022 | Dec 30, 2022 | — | $-0.52 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.42 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.26 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.25 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.14 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.37 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.37 | — | — |
Latest News
D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $15 Price Target
📈 PositiveBenzinga•Dec 9, 2025, 02:24 PM
Coya Therapeutics Announces Dosing Of ALS Patients In ALSTARS Trial Of COYA 302 Has Commenced
📈 PositiveBenzinga•Dec 9, 2025, 01:03 PM
Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target
📈 PositiveBenzinga•Nov 14, 2025, 01:19 PM
BTIG Maintains Buy on Coya Therapeutics, Raises Price Target to $16
📈 PositiveBenzinga•Nov 13, 2025, 06:19 PM
D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $15 Price Target
📈 PositiveBenzinga•Nov 12, 2025, 07:08 PM
Coya Therapeutics Q3 EPS $(0.13) Beats $(0.28) Estimate, Sales $3.564M Miss $3.700M Estimate
➖ NeutralBenzinga•Nov 12, 2025, 01:15 PM
Coya Therapeutics Reports Results Of In Vivo Animal Study Designed To Evaluate Effects Of COYA 303 In Well-Characterized In Vivo LPS Preclinical Mouse Model Of Systemic And Neurologic Inflammation
➖ NeutralBenzinga•Nov 4, 2025, 01:05 PM
Coya Therapeutics slides after pricing $20M stock offering
📉 NegativeSeeking Alpha•Oct 24, 2025, 10:43 AM
Coya Therapeutics Prices $20M Offering: 3,636,364 Shares At $5.50; 30-Day Option For 545,454 Shares; Closing Oct. 27, 2025
➖ NeutralBenzinga•Oct 24, 2025, 10:35 AM
Coya Therapeutics shares are trading lower after the company announced a proposed public offering of common stock.
📉 NegativeBenzinga•Oct 23, 2025, 08:59 PM
Coya Therapeutics Announces Proposed Public Offering of Common Stock, Size Not Given
➖ NeutralBenzinga•Oct 23, 2025, 08:31 PM
Coya Therapeutics shares are trading higher after Coya spokesperson told Benzinga "David Einhorn owns approximately 9.9% of Coya Therapeutics and included us in his annual shareholder letter today."
📈 PositiveBenzinga•Oct 14, 2025, 05:32 PM
Coya Therapeutics Spokesperson Tells Benzinga "David Einhorn owns approximately 9.9% of Coya Therapeutics and included us in his annual shareholder letter today."
📈 PositiveBenzinga•Oct 14, 2025, 05:28 PM
Watching Coya Therapeutics; Shares See Volume To The Upside, Traders Circulate Greenlight Capital Has A New Undisclosed Position In The Co; Writes 3 Paragraphs About It In Its Quarterly Investor Letter Believing It Has A Chance To Receive Fast Track FDA Approval
📈 PositiveBenzinga•Oct 14, 2025, 02:52 PM
BTIG Reiterates Buy on Coya Therapeutics, Maintains $15 Price Target
📈 PositiveBenzinga•Sep 30, 2025, 11:56 AM
D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $18 Price Target
📈 PositiveBenzinga•Sep 29, 2025, 01:48 PM
Coya Therapeutics Completes Patient Enrollment Of Investigator-Initiated, Open-Label Study With Low-Dose IL-2 And CTLA4-Ig Combination Treatment In Patients With Mild To Moderate Frontotemporal Dementia
📈 PositiveBenzinga•Sep 29, 2025, 12:20 PM
D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $18 Price Target
📈 PositiveBenzinga•Sep 22, 2025, 02:09 PM
Coya Therapeutics Launches Phase 2 ALSTARS Trial Of COYA 302 For ALS Across 25 Sites In U.S. And Canada
📈 PositiveBenzinga•Sep 22, 2025, 12:11 PM
D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $18 Price Target
📈 PositiveBenzinga•Sep 17, 2025, 11:43 AM
Frequently Asked Questions about COYA
What is COYA's current stock price?
Coya Therapeutics, Inc. (COYA) is currently trading at $5.49 per share. The stock has moved +3.58% today.
What is the analyst price target for COYA?
The average analyst price target for COYA is $17.00, based on 1 analyst.
What sector is Coya Therapeutics, Inc. in?
Coya Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is COYA's market cap?
Coya Therapeutics, Inc. has a market capitalization of $0.09 billion, making it a small-cap company.
Does COYA pay dividends?
No, Coya Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLNN
Clene Inc.
$6.68
Mkt Cap: $0.1B
CNTX
Context Therapeutics Inc.
$1.27
Mkt Cap: $0.1B
IMMX
Immix Biopharma, Inc.
$5.72
Mkt Cap: $0.2B
MGNX
MacroGenics, Inc.
$1.50
Mkt Cap: $0.1B
ORMP
Oramed Pharmaceuticals Inc.
$2.93
Mkt Cap: $0.1B
OVID
Ovid Therapeutics Inc.
$1.47
Mkt Cap: $0.1B
PLRX
Pliant Therapeutics, Inc.
$1.23
Mkt Cap: $0.1B
STTK
Shattuck Labs, Inc.
$3.15
Mkt Cap: $0.2B
WHWK
Whitehawk Therapeutics Inc
$2.56
Mkt Cap: $0.1B
ZNTL
Zentalis Pharmaceuticals, Inc.
$1.40
Mkt Cap: $0.1B
Explore stocks similar to COYA for comparison